Donor NK cell infusion for patients after allogeneic hematopoietic stem cell transplantation

Donor NK cell infusion for patients after allogeneic hematopoietic stem cell transplantation - Donor NK cell infusion for patients after allogeneic hematopoietic stem cell transplantation

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005138

Enrollment

Registered

2011-02-25

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia

Interventions

Donor NK cell infusion NK cell dose is limited by the number of contaminated T cells. Available to infusion repetitively after 2 weeks interval.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient has molecular relapsed disease. The patient has no other effective treatments. Informed consent is obtained.

Exclusion criteria

Exclusion criteria: The performance status is grater or equal to grade 2 (ECOG standard). The patient is on graft-versus-host disease. The patient has severe damages on heart, lung, kidney and liver.

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events(grater than or equal to CTCAE grade 3), graft-versus-host disease(grater than or equal to grade 1) and anti-tumor effect	—

Countries

Japan

Contacts

Public ContactKazuhiro Ikegame

Hyogo College of Medicine Hematology

kame@hyo-med.ac.jp0798-45-6886

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026